GENHOUSE BIO HKEX IPO Application Lapsed; Multiple Globally Competitive Drug Candidates Fail to Secure HKEX Listing
NewTimeSpace News: The listing application submitted by Suzhou Genhouse Bio Co., Ltd. to HKEX on 16 January 2026 has lapsed following the expiration of the six-month timeline. Huatai International served as the original sole sponsor.
The Company is a biopharmaceutical company with a differentiated and robust self-developed pipeline of innovative drug candidates built around the RAS signalling pathway and synthetic lethality mechanisms. According to CIC, several of its drug candidates hold globally leading positions in terms of clinical advancement against respective targets.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Suzhou Genhouse Bio Co., Ltd. Re-Files with HKEX, Turning Profitable with Half-Year Revenue Surge of RMB 557 Million
- HK Recently Listed Stocks Insight | LAIFUAL（03952.HK）：1H Revenue Up 80.1% YoY, 5.04 Million Cornerstone Lock-up Shares to Be Unlocked at End-December
- SEMIGHT (688808.SH): Board Approves Plan for H-Share Listing in HK
- JLC (001232.SZ): Plans H-Share Listing on HKEX Main Board
- CHINARES PHARMA (03320.HK): Unit completes 2026 bond issue at 1.48%
